Abstract
The present review examines whether the microRNA 7 (miR-7) holds potential for slowing Parkinson's disease (PD) progression. First, the accurate expression of miR-7 allows for normal development, physiology, and neurogenesis in the central nervous system, also keeping alpha-synuclein (α-Syn) at the physiological level. Second, patients with PD and parkinsonian MPTP-induced animals exhibit a significant decrease of miR-7 in brain areas associated with dopaminergic neurodegeneration. Depletion of miR-7 in the substantia nigra of clinical samples is related to α-Syn accumulation, loss of dopaminergic cells, and reduction of dopamine in the striatum. Therefore, the goal of a miR-7- replacement therapy is to downregulate α-Syn and other PD-related genes, achieving multi-target benefits regarding oxidative stress, mitochondrial health, cell glycolysis, apoptosis, and inhibition of inflammasome activation. While a disease-modifying drug is a major unmet need for the clinical management of PD, an miR-7-replacement therapy presents a striking potential against critical mechanisms of neuropathology. Such innovative treatment would reduce α-Syn accumulation in the Lewy bodies and preserve remaining neurons yet viable at the time of diagnosis, thus slowing disease progression from the early phase of PD characterized by a relatively mild motor impairment to an advanced and more disabling stage.
Keywords: miR-7, Parkinson's disease, Neurodegeneration, RNAi, MicroRNA, Synuclein, Lewy body, Synucleinopathy.
Current Gene Therapy
Title:miR-7 Replacement Therapy in Parkinson’s Disease
Volume: 18 Issue: 3
Author(s): Ricardo Titze-de-Almeida*Simoneide Souza Titze-de-Almeida
Affiliation:
- Technology for Gene Therapy Laboratory, Central Institute of Sciences, FAV, University of Brasilia, Brasília, 70910- 900,Brazil
Keywords: miR-7, Parkinson's disease, Neurodegeneration, RNAi, MicroRNA, Synuclein, Lewy body, Synucleinopathy.
Abstract: The present review examines whether the microRNA 7 (miR-7) holds potential for slowing Parkinson's disease (PD) progression. First, the accurate expression of miR-7 allows for normal development, physiology, and neurogenesis in the central nervous system, also keeping alpha-synuclein (α-Syn) at the physiological level. Second, patients with PD and parkinsonian MPTP-induced animals exhibit a significant decrease of miR-7 in brain areas associated with dopaminergic neurodegeneration. Depletion of miR-7 in the substantia nigra of clinical samples is related to α-Syn accumulation, loss of dopaminergic cells, and reduction of dopamine in the striatum. Therefore, the goal of a miR-7- replacement therapy is to downregulate α-Syn and other PD-related genes, achieving multi-target benefits regarding oxidative stress, mitochondrial health, cell glycolysis, apoptosis, and inhibition of inflammasome activation. While a disease-modifying drug is a major unmet need for the clinical management of PD, an miR-7-replacement therapy presents a striking potential against critical mechanisms of neuropathology. Such innovative treatment would reduce α-Syn accumulation in the Lewy bodies and preserve remaining neurons yet viable at the time of diagnosis, thus slowing disease progression from the early phase of PD characterized by a relatively mild motor impairment to an advanced and more disabling stage.
Export Options
About this article
Cite this article as:
Titze-de-Almeida Ricardo*, Titze-de-Almeida Souza Simoneide , miR-7 Replacement Therapy in Parkinson’s Disease, Current Gene Therapy 2018; 18 (3) . https://dx.doi.org/10.2174/1566523218666180430121323
DOI https://dx.doi.org/10.2174/1566523218666180430121323 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Feasibility of Delivering a Cognitive Behavioural Therapy-Based Resilience Curriculum to Young Mothers by Public Health Nurses
Adolescent Psychiatry Prospects of Magnetic Resonance Spectroscopy in Mouse Models of Alzheimers Disease
Current Medical Imaging Preliminary Study on Nematocyst Types and Venom Isolation of Cassiopea andromeda Forskål, 1775 (Scyphozoa, Cnidaria) from Turkey
Central Nervous System Agents in Medicinal Chemistry Role of Vitamins in Human Health and Nutrition: Sources and Morbidity
Current Nutrition & Food Science Immunomodulation in Polytrauma and Polymicrobial Sepsis - Where Do We Stand?
Recent Patents on Inflammation & Allergy Drug Discovery Structural Modifications of Matrine-Type Alkaloids
Mini-Reviews in Medicinal Chemistry Approaching Clinical Reality: Markers for Monitoring Systemic Inflammation and Sepsis
Current Molecular Medicine Leishmania Cysteine Proteinases: From Gene to Subunit Vaccine
Current Genomics Neuroproteomics in Paving the Pathway for Drug Abuse Research
Current Proteomics Manipulation and Engineering of Metabolic and Biosynthetic Pathway of Plant Polyphenols
Current Pharmaceutical Design Influence of Usnic Acid and its Derivatives on the Activity of Mammalian Poly(ADP-ribose)polymerase 1 and DNA Polymerase β
Medicinal Chemistry Brain Oxidative Markers in Stress: Possible New Drug Targets Against Neuroinflammation
Current Neuropharmacology ERRATUM 2
Current Neuropharmacology Crocin Protects Against Beta-Amyloid Peptide-Induced Apoptosis in PC12 Cells Via the PI3 K Pathway
Current Molecular Pharmacology The Effects of Obesity on Drug Metabolism in Children
Drug Metabolism Letters Diversity and Variability of the Effects of Nicotine on Different Cortical Regions of the Brain. Therapeutic and Toxicological Implications
Central Nervous System Agents in Medicinal Chemistry The Functions of Bursal Hexapeptide (BHP) on Immune Response and the Molecular Mechanism on Immature B Cell
Protein & Peptide Letters PEGylation of Proteins and Liposomes: a Powerful and Flexible Strategy to Improve the Drug Delivery
Current Drug Metabolism Integrins in Pulmonary Inflammatory Diseases
Current Pharmaceutical Design Drug Targets in Human T-Lymphotropic Virus Type 1 (HTLV-1) Infection
Infectious Disorders - Drug Targets